Antia Laboratories Inc.

New products

No new product at this time

Rapamycin


CAS Number: 53123-88-9

Molecular Weight: 914.17

Molecules Formula: C51H79NO13

Melting Point: 183℃-185℃

Appearance: White to Off-White Solid

Synonyms: (-)-Rapamycin; AY 22989; Antibiotic AY 22989; Cypher; NSC 226080; RAPA; RPM; Rapammune; Rapamune; SIIA 9268A; Sirolimus; Wy 090217;

Aplications:

Sirolimus, also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. A macrolide, sirolimus was first discovered as a product of the bacterium Streptomyces hygroscopicus in a soil sample from Easter Island-an island also known as "Rapa Nui", hence the name. It is marketed under the trade name Rapamune by Wyeth.

Sirolimus was originally developed as an antifungal agent. However, this was abandoned when it was discovered that it had potent immunosuppressive and antiproliferative properties. It has since been shown to prolong the life of mice and might also be useful in the treatment of certain cancers.

References:
1.Vézina C, Kudelski A, Sehgal SN (October 1975). "Rapamycin (AY-22,989), a new antifungal antibiotic.". J. Antibiot. 28 (10): 721–6. PMID 1102508.

2.Graziani EI (May 2009). "Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs". Nat Prod Rep 26 (5): 602–9. doi:10.1039/b804602f. PMID 19387497.

3.Harrison DE, Strong R, Sharp ZD, et al. (July 8, 2009). "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice". Nature 460 (7253): 392–5. doi:10.1038/nature08221. PMID 19587680.

4.Peces R, Peces C, Pérez-Dueñas V, et al. (January 16, 2009). "Rapamycin reduces kidney volume and delays the loss of renal function in a patient with autosomal-dominant polycystic kidney disease". NDT Plus (Oxford Journals) 2 (2): 133–135. doi:10.1093/ndtplus/sfn210.

5.Schwecke T, Aparicio JF, Molnár I, et al. (August 1995). "The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin". Proc. Natl. Acad. Sci. U.S.A. 92 (17): 7839–43. doi:10.1073/pnas.92.17.7839. PMID 7644502.

6.Sirolimus-induced signaling modifications in Kaposi's sarcoma with resolution in a liver transplant recipient. Clin Transplant 2010: 24: 127–132 Full text

7.Production of Novel Rapamycin Analogs by Precursor-Directed Biosynthesis. APPLIED AND ENVIRONMENTAL MICROBIOLOGY, Apr. 2005, p. 1971–1976 Full text

8.Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma. Pediatr Transplantation 2004: 8: 243–248 Full text

9.Increased frequency of regulatory T Cells and selection of highly potent CD62L+ cells during treatment of human lung transplant recipients with rapamycin. Journal compilation 2009 European Society for Organ Transplantation 23 (2010) 266–276 Full text

10.Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity. Journal compilation 2010 European Society for Organ Transplantation 23 (2010) 777–785 Full text

11.Severe sirolimus-induced acute hepatitis in a renal transplant recipient. Journal compilation 2010 European Society for Organ Transplantation 23 (2010) 967–970, DOI:10.1111/j.1432-2277.2010.01100.x Full text

12.Sirolimus addition to tacrolimus-based immunosuppression induces complete remission of post-transplant lymphoproliferative disorder in a liver transplant recipient. Journal compilation 2010 European Society for Organ Transplantation 23 (2010) 1068–1070. DOI:10.1111/j.1432-2277.2010.01121.x Full text

13.New process control strategy used in a rapamycin fermentation. Y. Chen et al. :Process Biochemistry 34 (1999) 383–389 Full text

The product is only for R&D purpose,not for human use.We will not take any responsibility for illegal use.

Cart  

(empty)